ALT

Altimmune Inc

$9.05

chg

-0.02 (-0.22%)

quotes and stock data may be delayed 15 minutes

52 wk low

7.8

52 wk hi

29.71

Cash

$226.5M

Burn Rate (Qtr)

$14.9M

Mkt Cap

$347.5m

Avg Volume

2,528,090

*cash/burn updated:

Q1 '21

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information.

No drug found

We have found any drug for this company yet

Drug | Disease (links)

Stage (next event)

Catalyst Date

NasoVAX

Influenza

Phase 2b

Initiation

Exp Date

A free account is required to see the catalyst dates, notes, and more!

HepTCell

Chronic hepatitis B

Phase 2

Data readout

Exp Date

A free account is required to see the catalyst dates, notes, and more!

NasoShield (Vaccine)

Anthrax, Bacterial infection

Phase 2

Initiation

Exp Date

A free account is required to see the catalyst dates, notes, and more!

T-COVID

COVID-19

Phase 1/2

Update

Exp Date

A free account is required to see the catalyst dates, notes, and more!

ALT-801 (GLP-1/Glucagon agonist)

Non-alcoholic steatohepatitis

Phase 1

Data readout

Exp Date

A free account is required to see the catalyst dates, notes, and more!

AdCOVID

COVID-19

Failed

Discontinued

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Loading Catalysts...

search in progress

Pipeline powered by

ALT

BPIQ_Logo_RGB-01.jpg

Company Profile

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating treatment for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). P

Recent Posts

See what the community is saying - click to see full post.

COVID-19 Therapeutic Stocks to Watch (June 2021)

COVID-19 Vaccine Stocks To Watch (June 2021)

Big-Mover™ Events June 2021

Smid-Cap Covid Vaccine update

Does the J&J Covid Vaccine Safety Issue, Provide an Opportunity for Biopharma investors?

ALT- AdCOVID (intranasal COVID-19 Vaccine) Readout Estimated Q1 2021